We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Spyre Therapeutics, Inc. Sample Contracts

OPEN MARKET SALE AGREEMENTSM
Open Market Sale Agreement • December 21st, 2018 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • New York
4,500,000 Shares Aeglea BioTherapeutics, Inc. COMMON STOCK UNDERWRITING AGREEMENT
Underwriting Agreement • April 19th, 2018 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • New York
INDEMNITY AGREEMENT
Indemnity Agreement • December 22nd, 2023 • Spyre Therapeutics, Inc. • Pharmaceutical preparations • Delaware

This Indemnity Agreement, dated as of [•], 2018 is made by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and [•], a director, officer or key employee of the Company or one of the Company’s subsidiaries or other service provider who satisfies the definition of Indemnifiable Person set forth below (“Indemnitee”).

REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • December 22nd, 2023 • Spyre Therapeutics, Inc. • Pharmaceutical preparations

This Registration Rights Agreement (this “Agreement”) is dated as of December 7, 2023, by and among Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

INDEMNIFICATION AGREEMENT
Indemnification Agreement • February 5th, 2024 • Spyre Therapeutics, Inc. • Pharmaceutical preparations

This Indemnification Agreement (this “Agreement”) is entered into as of by and between Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), and (the “Indemnitee”) and shall be deemed effective upon the earliest date that the Indemnitee is duly elected or appointed as a director or officer of the Company.

AEGLEA BIOTHERAPEUTICS, INC. Common Stock ($0.0001 par value per share) Capital on Demand™ Sales Agreement
Capital on Demand Sales Agreement • May 1st, 2017 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • New York

AEGLEA BIOTHERAPEUTICS, INC. a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JONESTRADING INSTITUTIONAL SERVICES LLC (the “Agent”), as follows:

REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • November 15th, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • New York

This Registration Rights Agreement (this “Agreement”) is made as of March 16, 2021 by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.

SEVERANCE AGREEMENT
Severance Agreement • March 8th, 2022 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This Severance Agreement (the “Agreement”) is entered into as of July 6, 2021 (the “Effective Date”) by and between Jonathan Alspaugh (the “Executive”) and Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”).

August 18, 2023 Heidy King-Jones Re: Offer of Employment Dear Heidy:
Employment Agreement • March 1st, 2024 • Spyre Therapeutics, Inc. • Pharmaceutical preparations

On behalf of Aeglea BioTherapeutics, Inc. (the “Company”), I am very pleased to offer you a position as Chief Legal Officer and Corporate Secretary (the “Role”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below.

AGREEMENT AND PLAN OF MERGER by and among: AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation; ASPEN MERGER SUB I, INC., a Delaware corporation; SEQUOIA MERGER SUB II, LLC, a Delaware limited liability company; and SPYRE THERAPEUTICS, INC., a...
Merger Agreement • December 22nd, 2023 • Spyre Therapeutics, Inc. • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of June 22, 2023, by and among AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation (“Parent”), ASPEN MERGER SUB I, INC., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), SEQUOIA MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and together with First Merger Sub, “Merger Subs”), and SPYRE THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • December 22nd, 2023 • Spyre Therapeutics, Inc. • Pharmaceutical preparations

This Registration Rights Agreement (this “Agreement”) is dated as of June 22, 2023, by and among Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

UNDERWRITING AGREEMENT 3,000,000 Shares AEGLEA BIOTHERAPEUTICS, INC. Common Stock ($0.0001 Par Value) EQUITY UNDERWRITING AGREEMENT
Underwriting Agreement • June 6th, 2017 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • New York

Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), proposes to sell to JonesTrading Institutional Services LLC (the “Underwriter”) an aggregate 3,000,000 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value (the “Common Stock”). The Company also proposes to sell at the Underwriter’s option an aggregate of up to 450,000 additional shares of the Company’s Common Stock (the “Option Shares”) as set forth below. The Firm Shares and the Option Shares (to the extent the aforementioned option is exercised) are herein collectively called the “Shares”.

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • March 18th, 2024 • Spyre Therapeutics, Inc. • Pharmaceutical preparations • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 18, 2024, by and among SPYRE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

OFFICE LEASE BETWEEN BARTON OAKS OFFICE CENTER, LLC (“LANDLORD”) AND AEGLEA DEVELOPMENT COMPANY, INC. (“TENANT”)
Office Lease • May 6th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations

This Office Lease (this “Lease”) is entered into by and between BARTON OAKS OFFICE CENTER, LLC, a Delaware limited liability company (“Landlord”), and AEGLEA DEVELOPMENT COMPANY, INC., a Delaware corporation (“Tenant”), and shall be effective as of the date set forth below Landlord’s signature (the “Effective Date”).

= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED BIOLOGICS MASTER...
Biologics Master Services Agreement • October 15th, 2024 • Spyre Therapeutics, Inc. • Pharmaceutical preparations

This Amended and Restated Biologics Master Services Agreement (this “Agreement”) is effective as of the latest date of signature (the “Effective Date”) and is between Spyre Therapeutics, Inc., a Delaware corporation, with an office at 221 Crescent Street, Building 17, Suite 102B, Waltham, MA 02453 (“Client”) and WuXi Biologics (Hong Kong) Limited, with its registered address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“Provider”), each of Client and Provider being a “Party,” and collectively the “Parties.”

AEGLEA BIOTHERAPEUTICS, INC. 11,652,830 Shares of Common Stock, par value $0.0001 Pre-Funded Warrants to Purchase 13,610,328 Shares of Common Stock Underwriting Agreement
Underwriting Agreement • April 28th, 2020 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • New York

Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 11,652,830 shares (the “Underwritten Shares”) of Common Stock, par value $0.0001 per share, of the Company (the “Common Stock”), pre-funded warrants to purchase an aggregate of 13,610,328 shares of Common Stock in the form attached hereto as Exhibit A (the “Warrants”) and, at the option of the Underwriters, up to an additional 3,789,473 shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Warrants are herein referred to as the “Underwritten Securities.” The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The Shares and Warrants are herein referred to as the “Securities.” The shares of Common Stock issuable upon exercise of the Warrants are herein referred to as the “Warrant

ASSET PURCHASE AGREEMENT dated as of July 27, 2023 by and between AEGLEA BIOTHERAPEUTICS, INC. and IMMEDICA PHARMA AB
Asset Purchase Agreement • December 22nd, 2023 • Spyre Therapeutics, Inc. • Pharmaceutical preparations • New York
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CELL LINE LICENSE AGREEMENT
Cell Line License Agreement • December 22nd, 2023 • Spyre Therapeutics, Inc. • Pharmaceutical preparations

This Cell Line License Agreement (“Agreement”), effective as of June 20, 2022 (“Effective Date”), is entered and made by and between WuXi Biologics (Hong Kong) Limited, having an address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“WuXi Biologics”) and Paragon Therapeutics, Inc., a Delaware corporation, with an office at 34 Cypress Rd., Arlington, MA 02474 (“Licensee”). WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties.”

AEGLEA BIOTHERAPEUTICS, INC. STOCK RESTRICTION AGREEMENT
Stock Restriction Agreement • December 22nd, 2023 • Spyre Therapeutics, Inc. • Pharmaceutical preparations • Delaware

This Stock Restriction Agreement (this “Agreement”) is made and entered into as of March 10, 2015 (the “Effective Date”) by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and (“Stockholder”).

LICENSE AGREEMENT
License Agreement • October 15th, 2024 • Spyre Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts

THIS LICENSE AGREEMENT (“Agreement”) is entered into and effective as of October 11, 2024 (the “Effective Date”), by and between Paragon Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Paragon”), having its principal place of business at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453, and Spyre Therapeutics, Inc. (“Spyre”), a corporation organized under the laws of the State of Delaware, having its principal place of business at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453. Paragon and Spyre are also referred to herein individually as a “Party”, or collectively as the “Parties.”

SEPARATION AND CONSULTING AGREEMENT AND GENERAL RELEASE OF CLAIMS
Separation and Consulting Agreement • December 22nd, 2023 • Spyre Therapeutics, Inc. • Pharmaceutical preparations • Texas

This SEPARATION AND CONSULTING AGREEMENT AND GENERAL RELEASE OF CLAIMS (this “Agreement”) is entered into by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and Jonathan Alspaugh (“Executive”). Executive and the Company are each referred to herein as a “Party” and collectively as the “Parties.”

VICE PRESIDENT SEVERANCE AGREEMENT
Severance Agreement • March 14th, 2016 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This Vice President Severance Agreement (the “Agreement”) is entered into as of January 14, 2016 (the “Effective Date”) by and between Henry L. Hebel (the “Employee”) and Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”).

= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDED AND RESTATED ANTIBODY DISCOVERY AND...
Antibody Discovery and Option Agreement • December 22nd, 2023 • Spyre Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts

THIS AMENDED AND RESTATED ANTIBODY DISCOVERY AND OPTION AGREEMENT (“Agreement”) is entered into and effective as of September 29, 2023 (the “New Effective Date”), by and among Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), Parapyre Holding LLC, a Delaware limited liability company (“Parapyre”) and Spyre Therapeutics, LLC (“Spyre”), a Delaware limited liability company and wholly-owned subsidiary of Aeglea BioTherapeutics, Inc. (“Aeglea”). Paragon, Parapyre and Spyre are also referred to herein individually as a “Party”, or collectively as the “Parties.”

LEASE TERMINATION AGREEMENT
Lease Termination Agreement • December 22nd, 2023 • Spyre Therapeutics, Inc. • Pharmaceutical preparations • Texas

THIS LEASE TERMINATION AGREEMENT (this “Agreement”) is made as of the 7th day of August, 2023 (“Effective Date”), by and between LAS CIMAS OWNER LP, a Delaware limited partnership (“Landlord”) and AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation (“Tenant”).

CONSULTING AGREEMENT
Consulting Agreement • March 1st, 2024 • Spyre Therapeutics, Inc. • Pharmaceutical preparations • Delaware

THIS CONSULTING AGREEMENT (together with the attached Exhibit A (the “Business Terms Exhibit”) and Exhibit B (the “EU Data Privacy Exhibit”), the “Agreement”), is made as of August 1, 2023 (the “Effective Date”) by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and Mark McKenna (“Consultant”). The Company desires to have the benefit of Consultant’s knowledge and experience, and Consultant desires to provide services to the Company, all as provided in this Agreement.

PATENT LICENSE AGREEMENT AGREEMENT NO. PM1401601
Patent License Agreement • September 14th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This Patent License Agreement is between the Licensor and the Licensee identified below (collectively, “Parties”, or singly, ‘Party”).

August 18, 2023 Heidy King-Jones Re: Offer of Employment Dear Heidy:
Offer of Employment • February 29th, 2024 • Spyre Therapeutics, Inc. • Pharmaceutical preparations

On behalf of Aeglea BioTherapeutics, Inc. (the “Company”), I am very pleased to offer you a position as Chief Legal Officer and Corporate Secretary (the “Role”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below.

Master Services Agreement
Master Services Agreement • September 14th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • North Carolina

This Master Services Agreement (this “Agreement”) dated December 24, 2013 (the “Effective Date”), between Aeglea Development Company, Inc., having a place of business at 815-A Brazos St. #101, Austin, TX 78701 (“Client”) and KBI Biopharma, Inc., having a place of business at 1101 Hamlin Road, Durham, North Carolina 27704 (“KBI Biopharma”) (Client and KBI Biopharma, each a “Party”, and collectively, the “Parties”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • November 15th, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 22, 2023, by and among AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

NOVATION AGREEMENT
Novation Agreement • December 22nd, 2023 • Spyre Therapeutics, Inc. • Pharmaceutical preparations • New York

This Novation Agreement (this “Novation Agreement”) dated as of July 21, 2023 (the “Effective Date”), is entered into by and among (i) Paragon Therapeutics, Inc., a Delaware corporation with an office at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (the “Transferor”), (ii) Aeglea Biotherapeutics, Inc., a Delaware corporation with an office at 221 Crescent Street Building 21, Suite 105, Waltham, MA 02453 (“Aeglea”), and (iii) WuXi Biologics (Hong Kong) Limited, a Hong Kong corporation with its registered address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (the “Counterparty”). All capitalized but undefined terms herein shall have the meanings ascribed to them in the Original Contracts (as defined below).

SPONSORED RESEARCH AGREEMENT NO. UTA13-001113
Sponsored Research Agreement • November 5th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This Sponsored Research Agreement (“Agreement”) is made between The University of Texas at Austin, Austin, Texas (“University”), an institution of higher education created by the Constitution and law of the State of Texas under The University of Texas System (“System”) and Aeglea Development Company, Inc., AERase, Inc., AEMase, Inc., AECase, Inc., AE4ase, Inc., AE5ase, Inc., and AE6ase, Inc., all Delaware C corporations with their principal place of business at 815 A Brazos St., #101, Austin TX 78701 (each a “Sponsor Entity” and collectively, “Sponsor”). Aeglea Development Company, Inc. may be referred to herein as the “Funding Sponsor” or “Sponsor Entity” as appropriate.

FIRST AMENDMENT TO OFFICE LEASE AND ASSIGNMENT AND ASSUMPTION OF LEASE
Office Lease • November 9th, 2016 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

THIS FIRST AMENDMENT TO OFFICE LEASE (this “Amendment”) is entered into as of the 20th day of September, 2016, by and between BARTON OAKS OFFICE CENTER, LLC, a Delaware limited liability company (“Landlord”), AEGLEA DEVELOPMENT COMPANY, INC., a Delaware corporation (“Assignor”) and AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation (“Assignee”).

AEGLEA BIOTHERAPEUTICS, INC. Common Stock ($0.0001 par value per share) Capital on Demand™ Sales Agreement
Capital on Demand Sales Agreement • May 20th, 2022 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • New York

Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through or to JonesTrading Institutional Services LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), on the terms set forth in this agreement (this “Agreement”).

AEGLEA BIOTHERAPEUTICS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT March 10, 2015
Investor Rights Agreement • June 16th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Delaware

This Amended and Restated Investor Rights Agreement (the “Agreement”) is entered into as of this 10th day of March 2015, by and among Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and each holder of the Company’s Series A Preferred Stock, $0.0001 par value per share (“Series A Preferred Stock”) and Series B Preferred Stock, $0.0001 par value per share (“Series B Preferred Stock”, referred to herein collectively with the Series A Preferred Stock as the “Preferred Stock”) listed on Schedule A (together with any subsequent investors, or transferees, who become parties hereto as “Investors” pursuant to Section 6.1 below, the “Investors”).

SEVERANCE AGREEMENT
Severance Agreement • December 22nd, 2023 • Spyre Therapeutics, Inc. • Pharmaceutical preparations • Texas

This Severance Agreement (the “Agreement”) is entered into as of April __, 2018 (the “Effective Date”) by and between __________________ (the “Executive”) and Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”).

SEVERANCE AND CHANGE IN CONTROL AGREEMENT
Severance and Change in Control Agreement • March 2nd, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This Severance and Change in Control Agreement (the “Agreement”) is entered into as of November 29, 2022 (the “Effective Date”) by and between Jeffrey M. Goldberg (the “Executive”) and Aeglea BioTherapeutics, Inc., a Delaware corporation (together with its subsidiaries, the “Company”).

AutoNDA by SimpleDocs
LEASE AGREEMENT BETWEEN LAS CIMAS OWNER LP, AS LANDLORD, AND AEGLEA BIOTHERAPEUTICS, INC. AS TENANT DATED APRIL 30, 2019
Lease Agreement • May 7th, 2019 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This Lease Agreement (this "Lease") is entered into as of April 30, 2019, between LAS CIMAS OWNER LP, a Delaware limited partnership ("Landlord"), and AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation ("Tenant").

CEO SERVERANCE AGREEMENT
Ceo Severance Agreement • September 14th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This CEO Severance Agreement (the “Agreement”) is entered into as of July 7, 2015 (the “Effective Date”) by and between David G. Lowe, Ph.D. (the “Executive”) and Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”).

SPONSORED RESEARCH AGREEMENT NO. UTA13-001113
Sponsored Research Agreement • June 16th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This Sponsored Research Agreement (“Agreement”) is made between The University of Texas at Austin, Austin, Texas (“University”), an institution of higher education created by the Constitution and law of the State of Texas under The University of Texas System (“System”) and Aeglea Development Company, Inc., AERase, Inc., AEMase, Inc., AECase, Inc., AE4ase, Inc., AE5ase, Inc., and AE6ase, Inc., all Delaware C corporations with their principal place of business at 815 A Brazos St., #101, Austin TX 78701 (each a “Sponsor Entity” and collectively, “Sponsor”). Aeglea Development Company, Inc. may be referred to herein as the “Funding Sponsor” or “Sponsor Entity” as appropriate.

September 20, 2024 Dr. Sheldon Sloan, M.D. Re: Offer of Employment Dear Sheldon:
Employment Agreement • November 7th, 2024 • Spyre Therapeutics, Inc. • Pharmaceutical preparations

On behalf of Spyre Therapeutics, Inc. (the “Company”), I am very pleased to offer you a position as Chief Medical Officer (the “Role”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below.

AMENDMENT NO. 1 TO THE NOVATION AGREEMENT
Novation Agreement • May 9th, 2024 • Spyre Therapeutics, Inc. • Pharmaceutical preparations

This Amendment No. 1 (the “Amendment”), effective as of April 25, 2024 (the “Amendment Effective Date”) to the Novation Agreement effective as of July 21, 2023 and executed on September 19, 2023 (the “Novation Agreement”) is entered into by and among (i) Paragon Therapeutics, Inc., a Delaware corporation with an office at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (the “Transferor”), (ii) Spyre Therapeutics, Inc. (f/k/a Aeglea BioTherapeutics, Inc.), a Delaware corporation with an office at 221 Crescent Street Building 23, Suite 105, Waltham, MA 02453 (“Spyre”), and (iii) WuXi Biologics (Hong Kong) Limited, a Hong Kong corporation with its registered address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (the “Counterparty”).

REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • March 18th, 2024 • Spyre Therapeutics, Inc. • Pharmaceutical preparations

This Registration Rights Agreement (this “Agreement”) is dated as of March 18, 2024, by and among Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

CONSULTING AGREEMENT
Consulting Agreement • June 16th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This Consulting Agreement (this “Agreement”), dated as of February 18, 2014, is entered into by and between Aeglea Development Company, Inc., a Delaware corporation (the “Company”), and George Georgiou (“Consultant”).

SEVERANCE AGREEMENT
Severance Agreement • March 2nd, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This Severance Agreement (the "Agreement") is entered into as of October 21, 2019 (the "Effective Date") by and between Michael Hanley (the "Executive") and Aeglea BioTherapeutics, Inc., a Delaware corporation (the "Company").

Amended and Restated Patent License Agreement Agreement No. PM1401501
Patent License Agreement • March 7th, 2019 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This Amended and Restated Patent License Agreement (“Patent License Agreement”) is between the Licensor and the Licensee identified below (collectively, “Parties”, or singly, “Party”).

AMENDMENT NO. 1 TO AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT
Investor Rights Agreement • March 7th, 2019 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Delaware

This Amendment No. 1 to Amended and Restated Investor Rights Agreement (this “Amendment”) is entered into as of December 4, 2018 by the undersigned parties to that certain Amended and Restated Investor Rights Agreement, dated as of March 10, 2015 (the “Rights Agreement”), by and among Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”) and the Investors. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Rights Agreement.

SPONSORED RESEARCH AGREEMENT NO. UTA13-001113
Sponsored Research Agreement • November 7th, 2017 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This Sponsored Research Agreement (“Agreement”) is made between The University of Texas at Austin, Austin, Texas (“University”), an institution of higher education created by the Constitution and law of the State of Texas under The University of Texas System (“System”) and Aeglea Development Company, Inc., AERase, Inc., AEMase, Inc., AECase, Inc., AE4ase, Inc., AE5ase, Inc., and AE6ase, Inc., all Delaware C corporations with their principal place of business at 815 A Brazos St., #101, Austin TX 78701 (each a “Sponsor Entity” and collectively, “Sponsor”). Aeglea Development Company, Inc. may be referred to herein as the “Funding Sponsor” or “Sponsor Entity” as appropriate.

RE: Board Service Agreement Dear Russ:
Board Service Agreement • June 16th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations

This letter sets forth the agreement between you and Aeglea BioTherapeutics, Inc. (the “Company”) regarding your Board service, effective as of June 15, 2015 (the “Effective Date”):

= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SECOND AMENDED AND RESTATED ANTIBODY...
Antibody Discovery and Option Agreement • August 7th, 2024 • Spyre Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts

This Second Amended and Restated Antibody Discovery and Option Agreement (“Agreement”) is entered into and effective as of May 14, 2024 (the “Second Restatement Effective Date”), by and among Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), Parapyre Holding LLC, a Delaware limited liability company (“Parapyre”), and Spyre Therapeutics, Inc. f/k/a Aeglea BioTherapeutics, Inc., a Delaware corporation (“Spyre”). Paragon, Parapyre and Spyre are also referred to herein individually as a “Party”, or collectively as the “Parties.”

July 18, 2017
Separation Agreement • August 9th, 2017 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This letter confirms the agreement (“Agreement”) between you and Aeglea Development Company, Inc. and its parent company Aeglea BioTherapeutics, Inc. (together, the “Company”) concerning the terms of your resignation and offers you the separation compensation we discussed in exchange for a general release of claims and covenant not to sue.

RECITALS
Cancer Research Grant Contract • June 16th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

Section C1.04 Conduct of Research or Service Provided. RECIPIENT understands that the Project must be conducted with full consideration for the ethical and medical implications of the research performed or services delivered and comply with all federal and state laws regarding the conduct of the research or service.

Amended and Restated Patent License Agreement Agreement No. PM1401501
Patent License Agreement • March 13th, 2018 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This Amended and Restated Patent License Agreement (“Patent License Agreement”) is between the Licensor and the Licensee identified below (collectively, “Parties”, or singly, “Party”).

Amended and Restated Patent License Agreement Agreement No. PM1401501
Patent License Agreement • March 23rd, 2017 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This Amended and Restated Patent License Agreement (“Patent License Agreement”) is between the Licensor and the Licensee identified below (collectively, “Parties”, or singly, “Party”).

April 23, 2024 Spyre Therapeutics, Inc. Waltham, MA 02453 Attention: Scott Burrows Re: 3(a)(9) Exchange Agreement Ladies and Gentlemen:
3(a)(9) Exchange Agreement • April 25th, 2024 • Spyre Therapeutics, Inc. • Pharmaceutical preparations

This letter agreement (the “Agreement”) confirms the agreement of Spyre Therapeutics, Inc. (the “Company”), and the holder of the Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share, of the Company (the “Series A Preferred Stock”) listed on Schedule I attached hereto (the “Stockholder”), pursuant to which the Stockholder has agreed to exchange 90,992 shares (the “Preferred Shares”) of Series A Preferred Stock, beneficially owned or owned of record, as applicable, by the Stockholder, in consideration for a total of 3,639,680 shares (the “Common Shares”) of Common Stock, par value $0.0001 per share, of the Company.

February 1, 2024 Cameron Turtle Re: Amendment to Amended and Restated Employment Letter Agreement Dear Cameron:
Employment Agreement • February 5th, 2024 • Spyre Therapeutics, Inc. • Pharmaceutical preparations • Washington

This letter, effective as of the date first set forth above (this “Amendment”), amends that certain amended and restated employment letter agreement between you and Spyre Therapeutics, Inc. (f/k/a Aeglea BioTherapeutics, Inc.) (the “Company”) dated November 22, 2023 (the “Agreement”).

= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED CELL LINE...
Cell Line License Agreement • October 15th, 2024 • Spyre Therapeutics, Inc. • Pharmaceutical preparations

This Amended and Restated Cell Line License Agreement (“Agreement”), effective as of the latest date of signature (the “Effective Date”), is entered and made by and between WuXi Biologics (Hong Kong) Limited, having an address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“WuXi Biologics”) and Spyre Therapeutics, Inc., a Delaware corporation, with an office at 221 Crescent Street, Building 17, Suite 102B, Waltham, MA 02453 (“Licensee”). WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties.”

LICENSE AND SUPPLY AGREEMENT
License and Supply Agreement • May 10th, 2021 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • New York

THIS LICENSE AND SUPPLY AGREEMENT (“Agreement”) is made effective as of the 21st day of March, 2021 (the “Effective Date”), by and between Immedica Pharma AB, a corporation organized and existing under the laws of Sweden with offices at Norrtullsgatan 15, SE 113 29 Stockholm, Sweden (“IMMEDICA”) and Aeglea BioTherapeutics, Inc., a corporation organized and existing under the laws of Delaware with offices at 805 Las Cimas Parkway, Suite 100, Austin, Texas, U.S.A. (“LICENSOR”). IMMEDICA and LICENSOR may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.

SPONSORED RESEARCH AGREEMENT NO. UTA13-001113
Sponsored Research Agreement • November 9th, 2016 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This Sponsored Research Agreement (“Agreement”) is made between The University of Texas at Austin, Austin, Texas (“University”), an institution of higher education created by the Constitution and law of the State of Texas under The University of Texas System (“System”) and Aeglea Development Company, Inc., AERase, Inc., AEMase, Inc., AECase, Inc., AE4ase, Inc., AE5ase, Inc., and AE6ase, Inc., all Delaware C corporations with their principal place of business at 815 A Brazos St., #101, Austin TX 78701 (each a “Sponsor Entity” and collectively, “Sponsor”). Aeglea Development Company, Inc. may be referred to herein as the “Funding Sponsor” or “Sponsor Entity” as appropriate.

June 22, 2023 Cameron Turtle Re: Offer of Employment Dear Cameron:
Employment Agreement • August 11th, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations

On behalf of Aeglea BioTherapeutics, Inc. (the “Company”), I am very pleased to offer you a position as Chief Operating Officer of the Company (the “Role”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below.

August 24, 2022
Transition and Resignation Agreement • March 2nd, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Massachusetts

This letter confirms the agreement (“Agreement”) between you and Aeglea BioTherapeutics, Inc. (the “Company”) concerning the terms of your transition and resignation from employment and offers you certain benefits to which you would not otherwise be entitled, conditioned upon your provision of a general release of claims and covenant not to sue now and upon the termination of your consultancy. If you agree to the terms outlined herein, please sign and return this Agreement to me in the timeframe outlined below.

EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • September 14th, 2015 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), is made and entered into as of July 7, 2015 (the “Effective Date”), by and between Aeglea Development Company, Inc., a Delaware corporation (the “Company”) and David G. Lowe (“Executive”).

SPONSORED RESEARCH AGREEMENT NO. UTA13-001113
Sponsored Research Agreement • March 14th, 2016 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Texas

This Sponsored Research Agreement (“Agreement”) is made between The University of Texas at Austin, Austin, Texas (“University”), an institution of higher education created by the Constitution and law of the State of Texas under The University of Texas System (“System”) and Aeglea Development Company, Inc., AERase, Inc., AEMase, Inc., AECase, Inc., AE4ase, Inc., AE5ase, Inc., and AE6ase, Inc., all Delaware C corporations with their principal place of business at 815 A Brazos St., #101, Austin TX 78701 (each a “Sponsor Entity” and collectively, “Sponsor”). Aeglea Development Company, Inc. may be referred to herein as the “Funding Sponsor” or “Sponsor Entity” as appropriate.

Something went wrong!
Loading CSS chunk 7092 failed. (error: https://www.lawinsider.com/static/assets-legacy/auth-view-ContinueWithEmailDialogView.92dcaad299.css)